News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | Iran Denies Direct Talks; Oil Price Back Above $100; Nasdaq 100 Rule Change May Open Door for SpaceX (March 31, 2026)2Bitcoin data points to ‘rare’ trading setup for relief rally to $71K3Iran's Potential Blockade of the Strait of Hormuz: Approaching April 6 and Growing Market Anxiety
WEC Energy's 0.94% Drop Overshadowed by 35% Volume Surge, Institutional Buys Outweigh Insider Sales, Ranks 374th
101 finance·2026/03/11 00:39
Zoetis Tumbles 1.53% as Institutional Selling Drives $360M Volume to 343rd Rank
101 finance·2026/03/11 00:33
Expand Energy's Shares Slide Despite Strong Earnings and Institutional Backing Trading Volume Ranks 349th
101 finance·2026/03/11 00:27
ADM's Shares Rise 2.16% as eVTOL Lawsuits Drive $350M in Trading Volume, Moving to 350th Place
101 finance·2026/03/11 00:27
Flutter Stock Drops 1.97% Amid Institutional Sell-Off and Earnings Shortfall, Ranking 346th in Trading Volume
101 finance·2026/03/11 00:27
Oklo's 329th-Ranked $380M Volume Marks 67.5% Slide From 52-Week High Amid Regulatory Delays and Insider Sales
101 finance·2026/03/11 00:19
Flash
11:16
Agios Pharmaceuticals (NASDAQ: AGIO) announced that, following a successful pre-SNDA meeting with the U.S. Food and Drug Administration (FDA), the company is actively advancing the accelerated approval process for its candidate drug mitapivat for the treatment of sickle cell disease (SCD).This key meeting clarified a feasible pathway for seeking accelerated approval of Mitapivat in the United States, marking an important step forward for the drug in addressing this serious hematological disease. The company plans to submit a marketing application to the FDA as soon as possible based on existing clinical data.
11:16
Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.The maximum review period is expected to last up to six months, starting from the date of resubmission. The company emphasized that this timeline is consistent with the FDA's standard procedures for handling BLA applications. If the review progresses smoothly, it will pave the way for the subsequent commercialization of related innovative therapies.
11:14
Trump Calls on Uncooperative Ally Nations: Either Buy Oil from the United States or Go Seize Oil in the Strait of HormuzBlockBeats News, March 31st, Trump posted on his Truth platform, saying, "All those countries that couldn't get aviation fuel through the Strait of Hormuz, like the UK that refused to participate in destroying Iran, I have some advice for you: First, buy from the US, we have abundant oil; Second, muster up the courage, go to the Strait of Hormuz, and seize the oil.
You must start learning to be self-reliant; the US will not help you like it used to. Iran has basically been destroyed. The most difficult part is over. Go get the oil by yourselves."
Trending news
MoreAgios Pharmaceuticals (NASDAQ: AGIO) announced that, following a successful pre-SNDA meeting with the U.S. Food and Drug Administration (FDA), the company is actively advancing the accelerated approval process for its candidate drug mitapivat for the treatment of sickle cell disease (SCD).
Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 days and initiate the formal review process.
News